Jeffrey Eisele - Dec 26, 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Development Officer
Signature
/s/ David Watson, attorney-in-fact for Jeffrey Eisele
Stock symbol
APLS
Transactions as of
Dec 26, 2023
Transactions value $
-$18,089
Form type
4
Date filed
12/28/2023, 04:13 PM
Previous filing
Feb 27, 2023
Next filing
Jan 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale -$3.93K -68 -0.13% $57.86 53.8K Dec 26, 2023 Direct F1
transaction APLS Common Stock Sale -$14.2K -235 -0.44% $60.23 53.6K Dec 27, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This represents shares sold to cover tax withholding on a Restricted Stock Unit release.
F2 Sale originated from established 10b5-1 trading plan.